

CURRICULUM VITAE ABREVIADO (CVA)

IMPORTANT – The Curriculum Vitae **cannot exceed 4 pages**. Instructions to fill this document are available in the website.

Part A. PERSONAL INFORMATION

First name	Laura		
Family name	Vallejo-Torres		
Gender (*)	Female	Birth date	19/09/1982
ID number	78499015s		
e-mail	Laura.vallejo@ulpgc.es	https://dmc.ulpgc.es/laura-vallejo-torres.html	
Open Researcher and Contributor ID (ORCID) (*)	0000-0001-5833-6066		

(*) Mandatory

A.1. Current position

Position	Associate Professor (Profesora Titular de Universidad)		
Initial date	15/12/2021		
Institution	Universidad de Las Palmas de Gran Canaria (ULPCG)		
Department/Center	Departamento de Métodos Cuantitativos en Economía y Gestión	Facultad de Economía, Empresa y Turismo	
Country	Spain	Teleph. number	(+34) 928450718
Key words	Health economics; economic evaluation; econometrics		

A.2. Previous positions (research activity interruptions, indicate total months)

Period	Position/Institution/Country/Interruption cause
2019-2021	Principal investigator, ULPGC, Spain
2017-2019	Post-doctoral researcher, ULPGC, Spain (4 months of maternity leave)
2016-2017	Part-time research associate, University College London, UK
2015-2017	Researcher, Fundación Canaria de Investigación Sanitaria, Spain (4 months of maternity leave)
2013-2015	Researcher, University de la Laguna, Spain
2011-2013	Principal Research Associate, University College London, UK
2010-2013	Visiting Lecturer, City University London, UK
2008-2011	Ph.D Researcher, University College London, UK
2006-2008	Research Fellow, Brunel University, UK

A.3. Education

Bachelor/Master/PhD	University/Country	Year
Ph.D in Health Economics	University College London, UK	2012
MSc in Health Economics	University of York, UK	2006
Bachelor degree in Economics	Universidad de Las Palmas de Gran Canaria, Spain	2004

Part B. CV SUMMARY

I have published over 50 scientific articles indexed in JCR, 22 of them as first author and 26 of them located in Q1. According to the ISI Web of Knowledge, the number of citations I have received is 1,100 and my h-index is 19 (in Google Scholar the number of citations increases to 1,937 and the h-index to 25). I have been a co-applicant and participated in three EU-funded projects. I have also participated in six national competitive projects, being the principal investigator in one of them. I have disseminated my work by presenting in more than 40 national and international conferences, and I have been invited to give several seminars at institutions such as Flinders University in Australia, Pompeu Fabra University in Spain,



Erasmus University Rotterdam in the Netherlands, and at the University of York in the UK. I have two research “sexenios” (2007-2012 and 2013-2018).

My research has focused on Health Economics, a multidisciplinary field that has allowed me to build considerable expertise in a wide spectrum of conceptual and methodological areas, such as economic evaluation, econometrics, inequality analysis, resource allocation, public health, among others. I have made significant contributions to this field, which have translated into publications in the most prestigious journals in this area of which I am the first author: Health Economics, Value in Health, Social Science and Medicine, the European Journal of Health Economics, the Lancet Global Health, among others.

My most recent line of research is on the estimation of the cost-effectiveness threshold to inform healthcare funding decisions and on broadening the scope of the cost-effectiveness framework. The outputs from this research in terms of publications, competitive funding, conference presentations and invited seminars demonstrate my abilities as an independent researcher, my capacity to lead a research team and the relevance and recognition of my line of research. In addition, this research has allowed me to maintain and lead several collaborations with international experts from prestigious institutions. Over and above the substantial scientific contributions, my work has also impacted on actual decision-making in health funding in Spain. Currently, the estimates of the cost-effectiveness threshold derived from the research I led are being used as the reference values in the reports conducted by the Network of Health Technology Assessment (HTA) agencies to draw conclusions about the cost-effectiveness of health interventions. These reports are a key tool for the Ministry of Health to make funding and price-setting decisions. Prior to that, I collaborated with the Canary Islands HTA agency in conducting this type of reports, being the author of over 20 reports submitted to the Ministry of Health.

I have been awarded several prizes and scholarships, including the prize to best paper by a young researcher presented at the Spanish Health Economics Conference, awarded by the Foundation of Applied Economic Studies (FEDEA) and the Capacity Building Studentship in Health Economics, granted by the UK Medical Research Council. I have organised several scientific meetings and I have been part of the scientific committee of national and international conferences. I was the president of the Spanish Association of Health Economics.

I have co-supervised two completed Ph.D theses (one submitted but defense is pending) and I am currently supervising two additional doctoral theses. I have also supervised over a dozen of Master theses.

Part C. RELEVANT MERITS

C.1. Publications (maximum 10)

1. **Vallejo-Torres L**, Claxton K, Edney LC, Karnon J, Lomas J, Ochalek J, Paulden M, Stadhouders N, Vanness DJ. Challenges of calculating cost-effectiveness thresholds. *Lancet Glob Health*. 2023;11(10):e1508. (Impact factor: 34.3; Q1)
2. **Vallejo-Torres L**. The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework. *Appl Health Econ Health Policy*. 2023;21(3):373-384. (Impact factor: 3.6; Q2)
3. **Vallejo-Torres L**, García-Lorenzo B, Edney LC, Stadhouders N, Edeka I, Castilla-Rodríguez I, García-Pérez L, Linertová R, Valcárcel-Nazco C, Karnon J. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries. *Appl Health Econ Health Policy*. 2022;20(3):337-349. (Impact factor: 3.6; Q2)
4. **Vallejo-Torres L**, García-Lorenzo B, Rivero-Arias O, Pinto-Prades JL. The societal monetary value of a QALY associated with EQ-5D-3L health gains. *Eur J Health Econ*. 2020;21(3):363-379. (Impact factor: 2.367; Q1)
5. **Vallejo-Torres L**, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. *Health Econ*. 2018;27(4):746-761 (Impact factor: 2.319; Q1)



6. **Vallejo-Torres L**, Morris S. Primary care supply and quality of care in England. *Eur J Health Econ*. 2018;19(4):499-519. (Impact factor: 2.601; Q1)
7. **Vallejo-Torres L**, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, García-Pérez L, Linertová R, Polentinos-Castro E, Serrano-Aguilar P. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? *Value Health*. 2016;19(5):558-66. (Impact factor: 3.279; Q1)
8. **Vallejo-Torres L**, Morris S. Income-related inequity in healthcare utilisation among individuals with cardiovascular disease in England-accounting for vertical inequity. *Health Econ*. 2013;22(5):533-53. (Impact factor: 2.232; Q1)
9. **Vallejo-Torres L**, Morris S. Factors associated with the use of primary care services: the role of practice nurses. *Eur J Health Econ*. 2011;12(4):373-81. (Impact factor: 1.755; Q1)
10. **Vallejo-Torres L**, Morris S. The contribution of smoking and obesity to income-related inequalities in health in England. *Soc Sci Med*. 2010 Sep;71(6):1189-98. (Impact factor: 2.742; Q1)

C.2. Congress (maximum 10)

1. Providing a routinely updatable estimation of the marginal cost per QALY in the Spanish NHS. UK Health Economists' Study Group meeting (HESG), Oxford University, UK, 2023. Oral presentation.
2. Incorporating economic evaluation evidence in therapeutic positioning reports. Spanish Health Economics Conference, Girona, Spain, 2023. Oral presentation.
3. The extended opportunity costs in the extended cost-effectiveness analysis framework. Spanish Health Economics Conference, Zaragoza, Spain, 2022. Oral presentation.
4. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions on Cost-Effectiveness Analyses? A Scoping Review in Four Countries. International Health Economics Association (iHEA), Virtual congress, 2021. Poster presentation.
5. Value-Based Pricing and Market Allocative Efficiency: How Should Cost-Effectiveness Thresholds be Set to "Optimally" Distribute Value between Payers and Developers? ISPOR, Virtual Congress, 2020. Oral presentation in organised session.
6. Estimating a cost-effectiveness threshold for the Spanish NHS. UK Health Economists' Study Group meeting (HESG), Gran Canaria, Spain, 2016. Oral presentation.
7. Primary care supply and quality of care. American Society of Health Economists Conference (ASHECon), Los Angeles, US, 2014. Oral presentation.
8. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Health Technology Assessment International (HTAi), Washington, US, 2014. Oral presentation.
9. On the measurement of vertical inequity in health care utilisation – emphasising the need dimension. International Health Economics Association Congress (iHEA), Toronto, Canada, 2011. Oral presentation.
10. Measuring vertical equity in health care utilisation using a concentration index approach: a comparison of estimates using socioeconomic ranks and need ranks. European Conference of Health Economics (ECHE), Helsinki, Finland, 2010. Oral presentation.

C.3. Research projects (maximum 10)

1. ID 101079838. IMAGINE. Improving antibiotic use in long term care facilities by infection prevention and control and antibiotic stewardship. European Union's 4th Health Programme. Principal investigator: Carl Llor (Institut Català de la Salut). 2023-2025. 1,649,020€. Role: Co-applicant/ Work Package leader.
2. ID 900024. HAPPY PATIENT. Health Alliance for Prudent Prescription and Yield of Antibiotics in a Patient-centered Perspective. European Union's 3rd Health Programme.



- Principal investigator: Carl Llor (Institut Català de la Salut). 2021-2023. 1,987,001€. Role: Co-applicant/Co-investigator.
3. RTI2018-096365-J-I00. How much should a health care system pay for health? – aligning population preferences and budget constraints. Ministerio de Ciencia, Innovación y Universidades. Programa Estatal de I+D+i orientada a los retos de la sociedad. Principal investigator: Laura Vallejo-Torres (Universidad de las Palmas de Gran Canaria). 2019-2022. 140,300€. Role: Principal Investigator.
 4. ECO2017-83771-C3-2-R. Public-Private Liaison in Health: quality, sustainability and changes in the Spanish framework. Ministerio de Ciencia, Innovación y Universidades. Programa Estatal de I+D+i orientada a los retos de la sociedad. Principal investigator: Beatriz González López Valcárcel (Universidad de las Palmas de Gran Canaria). 2018-2020. 32,670€. Role: Co-applicant/co-investigator.
 5. H2020-SC1-2016-2017. PECUNIA. ProgrammE in Costing, resource use measurement and outcome valuation for Use in multi-sectoral National and International health economic evaluations. European Commission Horizon 2020. Methods research for improved health economic evaluation. Principal investigator: Judith Simon (Medical University of Vienna). 2018-2020. 2,999,943,75€. Role: Co-applicant/co-investigator.
 6. PI15/01377. Effectiveness and cost-effectiveness of a multicomponent strategy to implement a clinical practice guideline and improve health outcomes in people with Systemic Erythematosus Lupus. Instituto de Salud Carlos III. Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016. Principal investigator: María del Mar Trujillo Martín (Servicio de Evaluación del Servicio Canario de la Salud). 2016-2018. 45,980€. Role: Co-applicant/co-investigator.
 7. PI14/01226. Cost-effectiveness evaluation of CIPA screening tool for patients with nutritional risk at hospital admission. Instituto de Salud Carlos III. Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016. Principal investigator: José Pablo Suarez Llanos (Complejo Hospital Universitario Nuestra Señora de Candelaria). 2015-2017. 22,385€. Role: Co-applicant/co-investigator
 8. ECO2013-48217-C2-1-R. Economics of prevention and lifestyles. From evidence to policy. Ministerio de Economía y Competitividad. Programa Estatal de I+D+i orientada a los retos de la sociedad. Principal investigator: Beatriz González López-Valcárcel (Universidad de las Palmas de Gran Canaria). 2015-2017. 45,100€. Role: Member of the work team.
 9. PI13/01040. Social-economic burden and health-related quality of life in patients with Systemic Lupus Erythematosus and their carers in Spain. Instituto de Salud Carlos III. Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016. Principal investigator: Renata Linertová (Servicio de Evaluación del Servicio Canario de Salud). 2014-2016. 15,981€. Role: Co-applicant/co-investigator.
 10. FP7-REGPOT-2012-CT2012-316137-IMBRAIN). Improving Biomedical Research and Innovation in the Canary Island (IMBRAIN). European Commission 7th Framework Programme. Principal Investigator: Rafael Alonso Solís (University of La Laguna). 2013-2015. 4,158,874€. Role: Appointed researcher.

C.4. Contracts, technological or transfer merits

1. González López-Valcárce B, Peiró S, Barber P, Pinilla J, Vallejo-Torres L, Castellón E, Solaz M, Zaera I. The value of knowledge in healthcare systems' responses to Covid-19. Contract with Fundación BBVA. 2021-2022.
2. Vallejo-Torres L. A technical report on the cost-effectiveness of herpes zoster vaccination. Contract with Fundación Canaria de Investigación Sanitaria (FUNCANIS). 2018.